Cargando…

Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases

Diagnosis-specific survival scores including a new score developed in 157 patients with brain metastases from small-cell lung cancer (SCLC) receiving whole-brain radiotherapy (WBRT) with 30 Gy in 10 fractions (WBRT-30-SCLC) were compared. Three prognostic groups were designed based on the 6-month su...

Descripción completa

Detalles Bibliográficos
Autores principales: Rades, Dirk, Hansen, Heinke C., Janssen, Stefan, Schild, Steven E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406817/
https://www.ncbi.nlm.nih.gov/pubmed/30781513
http://dx.doi.org/10.3390/cancers11020233
_version_ 1783401411174727680
author Rades, Dirk
Hansen, Heinke C.
Janssen, Stefan
Schild, Steven E.
author_facet Rades, Dirk
Hansen, Heinke C.
Janssen, Stefan
Schild, Steven E.
author_sort Rades, Dirk
collection PubMed
description Diagnosis-specific survival scores including a new score developed in 157 patients with brain metastases from small-cell lung cancer (SCLC) receiving whole-brain radiotherapy (WBRT) with 30 Gy in 10 fractions (WBRT-30-SCLC) were compared. Three prognostic groups were designed based on the 6-month survival probabilities of significant or almost significant factors, (age, performance score, number of brain metastases, extra-cerebral metastasis). Six-month survival rates were 6% (6–11 points), 44% (12–14 points) and 86% (16–19 points). The WBRT-30-SCLC was compared to three disease-specific scores for brain metastasis from SCLC, the original and updated diagnosis-specific graded prognostic assessment DS-GPA classifications and the Rades-SCLC. Positive predictive values (PPVs) used to correctly predict death ≤6 months were 94% (WBRT-30-SCLC), 88% (original DS-GPA), 88% (updated DS-GPA) and 100% (Rades-SCLC). PPVs to predict survival ≥6 months were 86%, 75%, 76% and 100%. For WBRT-30-SCLC and Rades-SCLC, differences between poor and intermediate prognoses groups and between intermediate and favorable prognoses groups were significant. For both DS-GPA classifications, only the difference between poor and intermediate prognoses groups was significant. Of these disease-specific tools, Rades-SCLC appeared to be the most accurate in identifying patients dying ≤6 months and patients surviving ≥6 months after irradiation, followed by the new WBRT-30-SCLC and the DS-GPA classifications.
format Online
Article
Text
id pubmed-6406817
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64068172019-03-21 Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases Rades, Dirk Hansen, Heinke C. Janssen, Stefan Schild, Steven E. Cancers (Basel) Article Diagnosis-specific survival scores including a new score developed in 157 patients with brain metastases from small-cell lung cancer (SCLC) receiving whole-brain radiotherapy (WBRT) with 30 Gy in 10 fractions (WBRT-30-SCLC) were compared. Three prognostic groups were designed based on the 6-month survival probabilities of significant or almost significant factors, (age, performance score, number of brain metastases, extra-cerebral metastasis). Six-month survival rates were 6% (6–11 points), 44% (12–14 points) and 86% (16–19 points). The WBRT-30-SCLC was compared to three disease-specific scores for brain metastasis from SCLC, the original and updated diagnosis-specific graded prognostic assessment DS-GPA classifications and the Rades-SCLC. Positive predictive values (PPVs) used to correctly predict death ≤6 months were 94% (WBRT-30-SCLC), 88% (original DS-GPA), 88% (updated DS-GPA) and 100% (Rades-SCLC). PPVs to predict survival ≥6 months were 86%, 75%, 76% and 100%. For WBRT-30-SCLC and Rades-SCLC, differences between poor and intermediate prognoses groups and between intermediate and favorable prognoses groups were significant. For both DS-GPA classifications, only the difference between poor and intermediate prognoses groups was significant. Of these disease-specific tools, Rades-SCLC appeared to be the most accurate in identifying patients dying ≤6 months and patients surviving ≥6 months after irradiation, followed by the new WBRT-30-SCLC and the DS-GPA classifications. MDPI 2019-02-16 /pmc/articles/PMC6406817/ /pubmed/30781513 http://dx.doi.org/10.3390/cancers11020233 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rades, Dirk
Hansen, Heinke C.
Janssen, Stefan
Schild, Steven E.
Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases
title Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases
title_full Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases
title_fullStr Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases
title_full_unstemmed Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases
title_short Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases
title_sort comparison of diagnosis-specific survival scores for patients with small-cell lung cancer irradiated for brain metastases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406817/
https://www.ncbi.nlm.nih.gov/pubmed/30781513
http://dx.doi.org/10.3390/cancers11020233
work_keys_str_mv AT radesdirk comparisonofdiagnosisspecificsurvivalscoresforpatientswithsmallcelllungcancerirradiatedforbrainmetastases
AT hansenheinkec comparisonofdiagnosisspecificsurvivalscoresforpatientswithsmallcelllungcancerirradiatedforbrainmetastases
AT janssenstefan comparisonofdiagnosisspecificsurvivalscoresforpatientswithsmallcelllungcancerirradiatedforbrainmetastases
AT schildstevene comparisonofdiagnosisspecificsurvivalscoresforpatientswithsmallcelllungcancerirradiatedforbrainmetastases